BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38632971)

  • 1. Re-188 lipiodol in hepatocellular carcinoma with portal vein thrombosis: a pilot study using novel chelating agent N-DEDC and its comparison with (A)HDD.
    Datta Gupta SS; Shamim SA; Gamanagatti S; Gupta P; Khan MA; Mallia MB; Chirayil V; Dash A; Bal C
    Nucl Med Commun; 2024 Jun; 45(6):510-518. PubMed ID: 38632971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma.
    Sundram F; Chau TC; Onkhuudai P; Bernal P; Padhy AK
    Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):250-7. PubMed ID: 15129708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma.
    Shinto AS; Karuppusamy KK; Kurup RER; Pandiyan A; Jayaraj AV
    Nucl Med Commun; 2021 Jan; 42(1):43-50. PubMed ID: 32956248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
    De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
    J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objective Tumor Response of Hepatocellular Carcinoma Obtained by Transarterial Radioembolization with Iodine-131-Lipiodol Versus Transarterial Chemoembolization for Patients with and without Portal Venous Thrombosis: A Controlled Interventional Trial.
    Oliveira Ribeiro MC; Moda KA; Alvarez M; Koga KH; Moriguchi SM; Carvalho FC; Pinheiro RSN; Qi X; Romeiro FG
    Acad Radiol; 2024 May; 31(5):1839-1848. PubMed ID: 38016824
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kumar N; Gupta P; Shamim SA; Chirayil V; Subramanian S; Mallia MB; Bal C
    World J Nucl Med; 2023 Jun; 22(2):114-123. PubMed ID: 37223628
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma. A single-center study based on a long-term follow-up.
    Ahmadzadehfar H; Habibi E; Ezziddin S; Wilhelm K; Fimmers R; Spengler U; Palmedo H; Strunk H; Schild HH; Biersack HJ; Risse J
    Nuklearmedizin; 2014; 53(2):46-53. PubMed ID: 24468919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis.
    Lambert B; Bacher K; De Keukeleire K; Smeets P; Colle I; Jeong JM; Thierens H; Troisi R; De Vos F; Van de Wiele C
    J Nucl Med; 2005 Aug; 46(8):1326-32. PubMed ID: 16085590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years' experience.
    Lintia-Gaultier A; Perret C; Ansquer C; Eugène T; Kraeber-Bodéré F; Frampas E
    Nucl Med Commun; 2013 Jul; 34(7):674-81. PubMed ID: 23587835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial.
    Kumar A; Srivastava DN; Chau TT; Long HD; Bal C; Chandra P; Chien le T; Hoa NV; Thulkar S; Sharma S; Tam le H; Xuan TQ; Canh NX; Pant GS; Bandopadhyaya GP
    Radiology; 2007 May; 243(2):509-19. PubMed ID: 17456873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol.
    Banka VK; Moon SH; Jeong JM; Seelam SR; Lee YS; Kim YJ; Lee DS; Chung JK
    Nucl Med Biol; 2015 Mar; 42(3):317-22. PubMed ID: 25537725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.
    Lambert B; Bacher K; Defreyne L; Gemmel F; Van Vlierberghe H; Jeong JM; Dierckx RA; Van de Wiele C; Thierens H; De Vos F
    J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study.
    Lambert B; Bacher K; Defreyne L; Van Vlierberghe H; Jeong JM; Wang RF; van Meerbeeck J; Smeets P; Troisi R; Thierens H; De Vos F; Van de Wiele C
    Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):344-52. PubMed ID: 16333675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience.
    Chen KT; Tsai KF; Leung HWC; Chan ALF; Wang SY; Liang HL; Tang SY; Chou CK; Chen HY; Chan SH; Li MF
    Medicina (Kaunas); 2021 Jul; 57(8):. PubMed ID: 34440985
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-lipiodol.
    Kumar A; Bal C; Srivastava DN; Thulkar SP; Sharma S; Acharya SK; Duttagupta S
    Eur J Gastroenterol Hepatol; 2006 Feb; 18(2):219-23. PubMed ID: 16394805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: Interim results of a prospective study.
    Dutta D; Tatineni T; Yarlagadda S; Gupte A; Reddy SK; Madhavan R; Nair H; Sasidharan A; Kannan R; Pottayil SG; Holla R; Sudhindran S
    Indian J Gastroenterol; 2021 Aug; 40(4):389-401. PubMed ID: 34694581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma.
    Boschi A; Uccelli L; Duatti A; Colamussi P; Cittanti C; Filice A; Rose AH; Martindale AA; Claringbold PG; Kearney D; Galeotti R; Turner JH; Giganti M
    Nucl Med Commun; 2004 Jul; 25(7):691-9. PubMed ID: 15208496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of transarterial chemoembolization in Egyptian patients with hepatocellular carcinoma and branch portal vein thrombosis.
    Abdella H; Shaker MK; Montasser IF; Sobhi M; Aly H; Sayed A; Saleh S; El Dorry A
    Indian J Gastroenterol; 2018 Mar; 37(2):127-132. PubMed ID: 29532323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.